


- [18] Cichon, S.; Winge, I.; Mattheisen, M.; Georgi, A.; Karpushova, A.; Freudenberg, J.; Freudenberg-Hua, Y.; Babadjanova, G.; Van Den Bogaert, A.; Abramova, L.I.; Kapiletti, S.; Knappskog, P.M.; McKinney, J.; Maier, W.; Jamra, R.A.; Schulze, T.G.; Schumacher, J.; Propping, P.; Rietschel, M.; Haavik, J.; Nothen, M.M. Brain-specific tryptophan hydroxylase 2 (TPH2): a functional Pro206Ser substitution and variation in the 5'-region are associated with bipolar affective disorder. *Hum. Mol. Genet.*, **2008**, *17*(1), 87-97.
- [19] Zhang, Y.Q.; Yuan, G.Z.; Li, G.L.; Yao, J.J.; Cheng, Z.H.; Chu, X.; Liu, C.J.; Liu, Q.H.; Wang, A.R.; Shi, G.Z.; Wang, B.H.; Cheng, Y.R.; Zhang, M.L.; Li, K. A case-control study on the risk factors for attempted suicide in patients with major depression. *Zhonghua Liu Xing Bing Xue Za Zhi*, **2007**, *28*(2), 131-135.
- [20] Ke, L.; Qi, Z.Y.; Ping, Y.; Ren, C.Y. Effect of SNP at position 40237 in exon 7 of the TPH2 gene on susceptibility to suicide. *Brain Res.*, **2006**, *1122*(1), 24-26.
- [21] Lopez de Lara, C.; Brezo, J.; Rouleau, G.; Lesage, A.; Dumont, M.; Alda, M.; Benkelfat, C.; Turecki, G. Effect of tryptophan hydroxylase-2 gene variants on suicide risk in major depression. *Biol. Psychiatry*, **2007**, *62*(1), 72-80.
- [22] Peters, E.J.; Slager, S.L.; McGrath, P.J.; Knowles, J.A.; Hamilton, S.P. Investigation of serotonin-related genes in antidepressant response. *Mol Psychiatry*, **2004**, *9*(9), 879-889.
- [23] Tzvetkov, M.V.; Brockmoller, J.; Roots, I.; Kirchheiner, J. Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment. *Pharmacogenet. Genomics*, **2008**, *18*(6), 495-506.
- [24] Gutknecht, L.; Jacob, C.; Strobel, A.; Kriegebaum, C.; Muller, J.; Zeng, Y.; Markert, C.; Escher, A.; Wendland, J.; Reif, A.; Mossner, R.; Gross, C.; Brocke, B.; Lesch, K.P. Tryptophan hydroxylase-2 gene variation influences personality traits and disorders related to emotional dysregulation. *Int. J. Neuropsychopharmacol.*, **2007**, *10*(3), 309-320.
- [25] Reuter, M.; Kuepper, Y.; Hennig, J. Association between a polymorphism in the promoter region of the TPH2 gene and the personality trait of harm avoidance. *Int. J. Neuropsychopharmacol.*, **2007**, *10*(3), 401-404.
- [26] Reuter, M.; Ott, U.; Vaitl, D.; Hennig, J. Impaired executive control is associated with a variation in the promoter region of the tryptophan hydroxylase 2 gene. *J. Cogn. Neurosci.*, **2007**, *19*(3), 401-408.
- [27] Strobel, A.; Dreisbach, G.; Muller, J.; Goschke, T.; Brocke, B.; Lesch, K.P. Genetic variation of serotonin function and cognitive control. *J. Cogn. Neurosci.*, **2007**, *19*(12), 1923-1931.
- [28] Stoltenberg, S.F.; Glass, J.M.; Chermack, S.T.; Flynn, H.A.; Li, S.; Weston, M.E.; Burmeister, M. Possible association between response inhibition and a variant in the brain-expressed tryptophan hydroxylase-2 gene. *Psychiatr. Genet.*, **2006**, *16*(1), 35-38.
- [29] Nielsen, D.A.; Barral, S.; Proudnikov, D.; Kellogg, S.; Ho, A.; Ott, J.; Kreek, M.J. TPH2 and TPH1: association of variants and interactions with heroin addiction. *Behav. Genet.*, **2008**, *38*(2), 133-150.
- [30] Ujike, H.; Harano, M.; Inada, T.; Yamada, M.; Komiyama, T.; Sekine, Y.; Sora, I.; Iyo, M.; Katsu, T.; Nomura, A.; Nakata, K.; Ozaki, N. Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. *Pharmacogenomics. J.*, **2003**, *3*(4), 242-247.
- [31] Ujike, H. Stimulant-induced psychosis and schizophrenia: the role of sensitization. *Curr. Psychiatry Rep.*, **2002**, *4*(3), 177-184.
- [32] Schneider, S.; Roessli, D.; Excoffier, L. Arlequin: a software for population genetics data analysis. Version 2.000. Genetics and Biometry Lab, Department of Anthropology, University of Geneva, **2000**.
- [33] Uhl, G.R.; Hall, F.S.; Sora, I. Cocaine, reward, movement and monoamine transporters. *Mol. Psychiatry*, **2002**, *7*(1), 21-26.
- [34] Dahl, J.P.; Cubells, J.F.; Ray, R.; Weller, A.E.; Lohoff, F.W.; Ferraro, T.N.; Oslin, D.W.; Kampman, K.M.; Dackis, C.; Tang, Y.; Gelernter, J.; Kranzler, H.R.; O'Brien, C.P.; Berrettini, W.H. Analysis of variations in the tryptophan hydroxylase-2 (TPH2) gene in cocaine dependence. *Addict. Biol.*, **2006**, *11*(1), 76-83.



Contents lists available at ScienceDirect

# Progress in Neuro-Psychopharmacology & Biological Psychiatry

journal homepage: [www.elsevier.com/locate/pnp](http://www.elsevier.com/locate/pnp)

## Association analysis of the GDNF gene with methamphetamine use disorder in a Japanese population

Tomoko Yoshimura <sup>a,1</sup>, Hinako Usui <sup>b,\*</sup>, Nagahide Takahashi <sup>c</sup>, Akira Yoshimi <sup>d</sup>, Shinichi Saito <sup>e</sup>, Branko Aleksic <sup>b,n</sup>, Hiroshi Ujike <sup>f,m</sup>, Toshiya Inada <sup>g,m</sup>, Mitsuhiko Yamada <sup>h,m</sup>, Naohisa Uchimura <sup>i,m</sup>, Nakao Iwata <sup>j,m,n</sup>, Ichiro Sora <sup>k,m</sup>, Masaomi Iyo <sup>l,m</sup>, Norio Ozaki <sup>b,m,n</sup>

<sup>a</sup> Division of Clinical Science and Neuropsychopharmacology, Graduate School of Pharmacy, Meijo University, Aichi, Japan

<sup>b</sup> Department of Psychiatry, Nagoya University Graduate School of Medicine, Aichi, Japan

<sup>c</sup> Laboratory of Molecular Neuropsychiatry, Department of Psychiatry, Mount Sinai School of Medicine, NY, USA

<sup>d</sup> Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Aichi, Japan

<sup>e</sup> Matuzakakousei Hospital, Mie, Japan

<sup>f</sup> Department of Neuropsychiatry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

<sup>g</sup> Seiwa Hospital, Institute of Neuropsychiatry, Tokyo, Japan

<sup>h</sup> National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan

<sup>i</sup> Department of Psychiatry, Kurume University Graduate School of Medicine, Kyushu, Japan

<sup>j</sup> Department of Psychiatry, Fujita Health University School of Medicine, Aichi, Japan

<sup>k</sup> Department of Biological Psychiatry, Tohoku University Graduate School of Medicine, Sendai, Japan

<sup>l</sup> Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba, Japan

<sup>m</sup> Japanese Genetics Initiative for Drug Abuse (JGIDA), Japan

<sup>n</sup> CREST, Japan Science and Technology Agency, Tokyo, Japan

### ARTICLE INFO

#### Article history:

Received 21 September 2010

Received in revised form 7 March 2011

Accepted 2 April 2011

Available online 14 April 2011

#### Keywords:

Association study

Dopamine

GDNF

Genetic disorders

Methamphetamine

Single nucleotide polymorphism

### ABSTRACT

Methamphetamine (MAP) dependence is a highly heritable and aberrant dopaminergic signaling that has been implicated in the disease. Glial cell line-derived neurotrophic factor (GDNF), which plays an important role in the survival of dopaminergic neurons, may be involved in this disorder. In this study, we examined the association between GDNF and MAP dependence using a Japanese population-based sample.

We selected eight single nucleotide polymorphisms (SNPs) in the GDNF locus for the association analysis. When patients with MAP dependence were divided into two subgroups consisting of multi-substance and MAP-only users, we detected a significant association between these two groups and the tagging SNP, rs2910704 (after Bonferroni's correction; allele  $P = 0.034$ ). Thus, GDNF is likely to be related to the severity of MAP use in the Japanese population.

© 2011 Elsevier Inc. All rights reserved.

### 1. Introduction

Methamphetamine (MAP) dependence is a serious public health problem that has reached epidemic proportions worldwide (Elkashef et al., 2008). Repeated use of MAP induces a strong psychological

**Abbreviations:** MAP, methamphetamine; GDNF, Glial cell line-derived neurotrophic factor; DA, dopamine; UTR, untranslated region; SNP, single nucleotide polymorphism; GFRA, GDNF family receptor alpha; RET, rearranged during transfection; JGIDA, Japanese Genetics Initiative for Drug Abuse; S.D., standard deviation; MAF, minor allele frequency; HW, Hardy-Weinberg equilibrium; LD, linkage disequilibrium; DAT, dopamine transporter.

\* Corresponding author at: Department of Psychiatry and Psychobiology, Nagoya University, Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya 466-8550, Japan. Tel.: +81 52 744 2282; fax: +81 52 744 2293.

E-mail address: [hinako@v001.vaio.ne.jp](mailto:hinako@v001.vaio.ne.jp) (H. Usui).

<sup>1</sup> These authors contributed equally to this work.

0278-5846/\$ – see front matter © 2011 Elsevier Inc. All rights reserved.

doi:10.1016/j.pnpbp.2011.04.003

dependence and results in the development of psychotic symptoms such as psychosis, attempted suicide, craving, and depression (Aoyama et al., 2006; Nakama et al., 2008). Numerous family and twin epidemiological studies have suggested that MAP dependence is a highly heritable disorder (the estimated heritability is 30–60%) (Kendler et al., 2005; Aoyama et al., 2006; Lichtenstein et al., 2009). Thus, a number of molecular genetic studies have been conducted worldwide to elucidate the vulnerable genes associated with this disorder (Aoyama et al., 2006; Kishi et al., 2010; Okochi et al., 2009).

Aberrant dopaminergic transmission has long been implicated in the development of MAP dependence (Freedman, 2003; Yui et al., 2000). It is well known that glial cell line-derived neurotrophic factor (GDNF) is one of the most potent neurotrophic factor influencing the dopaminergic function. (Carnicella and Ron, 2009). Indeed GDNF plays an important role in the survival and neurite outgrowth of midbrain dopaminergic neurons (Krieglstein et al., 1995; Lin et al.,

1993). Furthermore, GDNF modulates the activity/excitability of midbrain dopamine (DA) neurons (Yang et al., 2001; Wang et al., 2003) as well as DA uptake (Lin et al., 1993). These observations suggest that GDNF is important for the development and maintenance of DA signaling.

An animal study has provided direct evidence of the involvement of GDNF in MAP dependence. Reduction in the expression of *GDNF* potentiates MAP self-administration, enhances motivation for mice to take MAP, increases vulnerability to drug-primed reinstatement, and prolongs cue-induced reinstatement of MAP-seeking behavior that had been previously suppressed (Yan et al., 2007). Of note, GDNF is implicated not only in the control of MAP intake and seeking but also in drug abuse in general (Ghitza et al., 2010; Carnicella and Ron, 2009). Manipulations that modulate the amount of GDNF in the brain decrease cocaine-induced conditioned place preference and reduce cocaine and ethanol self-administration in rats (Carnicella et al., 2008; Messer et al., 2000; Green-Sadan et al., 2003, 2005).

Thus, changes in the expression or function of GDNF may affect dopaminergic signaling, favoring the development of MAP-seeking behaviors.

MAP-induced psychosis and schizophrenia (the paranoid type in particular) show very similar symptoms (Sato et al., 1992), and genetic association between *GDNF* and schizophrenia have been repeatedly reported (Lee et al., 2001; Michelato et al., 2003). To the best of our knowledge, however, the association of *GDNF* with MAP dependence has not been investigated. Therefore, our current study aimed to examine the possible association of SNPs in *GDNF* with susceptibility for MAP dependence in Japanese population.

## 2. Materials and methods

### 2.1. Participants

This study was approved by the ethics committees of each institution of the Japanese Genetics Initiative for Drug Abuse (JGIDA) including the Nagoya University Graduate School of Medicine and Fujita Health University. All patients were unrelated to each other and were ethnically Japanese. Written informed consent was obtained from each patient.

A total of 219 patients with MAP dependence (178 males, 41 females and mean age  $\pm$  standard deviation (S.D.),  $37.1 \pm 11.8$  years) and 383 normal controls (160 males, 223 females and mean age  $\pm$  S.D.,  $40.0 \pm 14.6$  years) were genotyped. Patients with MAP dependence were diagnosed according to the ICD-10-DCR criteria, with the consensus of at least two experienced psychiatrists on the basis of empirical diagnostic interviews and review of medical records. Along with the case-control comparison, associations of five clinical features of the patients with MAP dependence were also examined, including

age of first use, latency of psychosis, multi-substance use, prognosis of psychosis, and spontaneous relapse of psychotic symptoms (Morita et al., 2005).

A total of 106 patients (48.4%) consumed MAP before the age of 20 years, and 109 patients (49.8%) first consumed MAP after they were 20 years old. The latency of psychosis was less than 3 years after the first MAP consumption in 95 patients (43.4%), and 3 or more years in 82 patients (37.4%). A total of 60 patients (27.4%) abused only MAP during their lifetime, and 152 patients (69.4%) abused drugs in addition to MAP in the past or present. A total of 107 patients (48.9%) were diagnosed as the transient type, and 81 patients (37.0%) were diagnosed as the prolonged type. The numbers of patients with and without a history of spontaneous relapse were 80 (36.5%) and 130 (59.4%), respectively.

### 2.2. Tagging SNP selection

GDNF is a trophic factor for dopaminergic neurons. The genomic structure of the *GDNF* locus covers a 24-kb interval at 5p12–p13.1. The locus contains three exons coding for a cDNA of 4.6 kb including large 5'- and 3'-UTRs (Grimm et al., 1998).

We first consulted the HapMap database (release #22/phase II; population: Japanese in Tokyo) to obtain SNPs throughout the entire coding region of *GDNF* as well as in the flanking regions 500 bp upstream and 500 bp downstream of the coding regions. Twenty-three SNPs were found in the HapMap Japanese sample.

The longest isoform was selected from the three alternately spliced isoforms of GDNF. We chose representative SNPs with the criteria of minor allele frequency (MAF)  $>0.10$  and  $r^2 > 0.80$ , using Haploview version 3.32 software (<http://www.broadinstitute.org/mpg/haploview>) (Barrett et al., 2005), and defined these as tagging SNPs.

As a result, eight tagging SNPs were chosen. The gene structure of *GDNF* and the position of each SNP are shown in Fig. 1.

### 2.3. SNP genotyping

Genotyping of tagging SNPs was carried out using TaqMan assays (Applied Biosystems, Foster City, CA). TaqMan probes and Universal PCR Master Mix were obtained from Applied Biosystems. A 5- $\mu$ l total reaction volume was used, and allelic-specific fluorescence was measured using the ABI PRISM 7900 Sequence Detector System (Applied Biosystems). Sequences of the individual primer pairs are available upon request. To exclude low-quality DNA samples or genotyping probes, data sets were filtered on the basis of tSNP genotype call rates (100% completeness) or deviation from the Hardy-Weinberg equilibrium (HWE) ( $P = 0.05$ ) in the control sample. Participants whose percentage of missing genotypes was more than 10% or who had




Fig. 1. Genomic structure of *GDNF* and the SNPs used in our association analysis. Vertical bars represent exons in *GDNF*, and the number under each arrow is the SNP ID.

**Table 1**Association analysis of tagSNPs in *GDNF* with MAP dependence.

No.	SNP ID	M/m	Phenotype	N	Genotype			MAF	P-value		Global P-value
					M/M	M/m	m/m		Genotype	Allele	
1	rs2973033 exon1	A/G	MAP	Case	205	112	72	21	0.28	0.14	0.67
				Control	381	202	155	24	0.27		
2	rs10941370 intron2	T/C	MAP	Case	204	78	94	32	0.39	0.82	0.79
				Control	381	145	183	53	0.38		
3	rs12518844 intron2	G/A	MAP	Case	205	85	91	29	0.36	0.57	0.79
				Control	381	154	183	44	0.36		
4	rs2910702 intron2	A/G	MAP	Case	206	85	101	20	0.34	0.55	0.93
				Control	382	164	172	46	0.34		
5	rs2910704 intron2	G/C	MAP	Case	206	88	94	24	0.34	0.47	0.25
				Control	381	143	190	48	0.38		
6	rs884344 intron2	A/C	MAP	Case	205	128	69	8	0.21	0.40	0.18
				Control	381	219	140	22	0.24		
7	rs1549250 intron2	G/T	MAP	Case	205	95	90	20	0.32	0.25	0.10
				Control	381	198	158	25	0.27		
8	rs2973049 intron2	G/A	MAP	Case	205	51	111	43	0.48	0.24	0.96
				Control	380	109	178	93	0.48		

M: major allele and m: minor allele.

MAF: minor allele frequency.

evidence of possible DNA contamination were excluded from the subsequent analyses. Finally, the clustering performance of the allelic discrimination assay was visually inspected for all SNPs.

#### 2.4. Statistical analysis

Genotype deviation from HWE was evaluated with the  $\chi^2$ -test. Genotypic association of SNPs that deviated from HWE was analyzed using Cochran–Armitage trend tests for the multiplicative model of inheritance (Balding, 2006). Genotypic and allelic associations were performed with SPSS version 14.0J (Tokyo, Japan) and Haploview software version 3.32, respectively. The significance level for all statistical tests was set at 0.05. Bonferroni's corrections were used for multiple comparisons; MAP P corrected = 0.05/48 [eight SNPs × two genetic analyses × three phenotypes (age of first use, multiple substance abuse and prognosis of psychosis)]. The linkage disequilibrium (LD) block was defined by Haploview 3.32. When the haplotype frequency in each block was over 5%, haplotypic analysis was performed with Unphased version 3.1.3 (Dudbridge, 2008), which was not a tagging SNP as defined by the Tagger program. Power calculations were performed using the genetic statistical package on a Genetic Power Calculator (<http://pngu.mgh.harvard.edu/~purcell/gpc/>) (Purcell et al., 2003).

### 3. Results

The genotypic and allelic frequencies of each SNP in patients with MAP dependence and normal controls are summarized in Table 1. The observed genotypic frequencies of all SNPs were within the distribution expected according to HWE. Neither the genotypic nor the allelic frequencies of the eight tagging SNPs for *GDNF* differed significantly between patients with MAP dependence and controls. As a result of LD analysis of 383 normal controls, one LD block was defined. The distribution of haplotypic frequencies at this block did not differ significantly between patients with MAP dependence and normal controls (global P value = 0.46). More than 80% power in detecting association was obtained when the prevalence of MAP dependence was set at 0.3% and the genotype relative risk was set at 1.40–1.45 under a multiplicative model of inheritance.

Next, we analyzed these cohorts based on the five clinical features of MAP dependence. First, a significant association was observed for rs2910704 (genotype, P = 0.01) between MAP-dependent patients whose age at first MAP consumption was younger than 20 years old and those who were older than 20 years at their first MAP consumption (Table 2). When patients with MAP dependence were divided into two subgroups of multi-substance and MAP-only users, a significant difference was observed between these two groups for the

**Table 2**Genotype and allele frequencies of *GDNF* in the age of first use.

No.	SNP ID	M/m	Group	N	Genotype			MAF	P-value	
					M/M	M/m	m/m		Genotype	Allele
1	rs2973033 exon1	A/G	≥20 years	97	50	40	7	0.28	0.14	0.91
			<20 years	104	59	31	14	0.28		
2	rs10941370 intron2	T/C	≥20 years	97	41	42	14	0.36	0.65	0.44
			<20 years	103	37	50	16	0.40		
3	rs12518844 intron2	G/A	≥20 years	97	42	43	12	0.35	0.83	0.60
			<20 years	104	43	45	16	0.37		
4	rs2910702 intron2	A/G	≥20 years	97	39	49	9	0.35	0.91	0.96
			<20 years	105	44	50	11	0.34		
5	rs2910704 intron2	G/C	≥20 years	97	38	53	6	0.34	<b>0.01</b>	0.64
			<20 years	105	48	39	18	0.36		
6	rs884344 intron2	A/C	≥20 years	97	57	37	3	0.22	0.49	0.63
			<20 years	104	67	32	5	0.20		
7	rs1549250 intron2	G/T	≥20 years	97	45	43	9	0.31	0.90	0.97
			<20 years	104	50	43	11	0.31		
8	rs2973049 intron2	G/A	≥20 years	97	28	49	20	0.46	0.55	0.41
			<20 years	104	23	58	23	0.50		

Bold numbers represent significant P-values.

M: major allele and m: minor allele.

MAF: minor allele frequency.

**Table 3**  
Association analysis of tagSNPs in *GDNF* in the multi substance use.

No.	SNP ID	M/m	Group	N	Genotype			MAF	P-value	
					M/M	M/m	m/m		Genotype	Allele
1	rs2973033 exon1	A/G	No	57	26	21	10	0.36	0.09	<b>0.03</b>
			Yes	141	82	48	11	0.25		
2	rs10941370 intron2	T/C	No	57	22	23	12	0.41	0.46	0.53
			Yes	140	54	66	20	0.38		
3	rs12518844 intron2	G/A	No	57	24	23	10	0.38	0.67	0.82
			Yes	141	57	65	19	0.37		
4	rs2910702 intron2	A/G	No	57	34	19	4	0.24	<b>0.007</b>	<b>0.01</b>
			Yes	142	50	77	15	0.38		
5	rs2910704 intron2	G/C	No	57	15	30	12	0.47	<b>0.003</b>	<b>0.0007</b>
			Yes	142	70	60	12	0.30		
6	rs884344 intron2	A/C	No	57	30	23	4	0.27	0.12	<b>0.04</b>
			Yes	141	94	43	4	0.18		
7	rs1549250 intron2	G/T	No	57	26	28	3	0.30	0.38	0.59
			Yes	141	65	60	16	0.33		
8	rs2973049 intron2	G/A	No	57	18	28	11	0.44	0.49	0.33
			Yes	141	33	77	31	0.49		

Bold numbers represent significant P-values.

M: major allele and m: minor allele.

MAF: minor allele frequency

tagging SNPs, rs2973033 (allele,  $P=0.03$ ), rs2910702 (genotype,  $P=0.007$  and allele,  $P=0.01$ ), rs2910704 (genotype,  $P=0.003$  and allele,  $P=0.0007$ ), and rs884344 (allele,  $P=0.04$ ) (Table 3). In addition, there was a significant difference between the transient type and the prolonged type for rs2973033 (allele,  $P=0.02$ ) (Table 4). No significant differences were found in the latency of psychosis or spontaneous relapse of psychotic symptoms (data not shown). After Bonferroni's correction, three SNPs were no longer significant, but rs2910704 remained significant (allele,  $P=0.034$ ) between multi-substance and MAP-only users (Table 3).

#### 4. Discussion

Our results of the association analysis of MAP dependence suggest that *GDNF* may be related to the severity of MAP dependence in the Japanese population. There was no significant difference in the frequency of any of the tagging SNPs between MAP users and normal controls. However, when patients with MAP dependence were divided into two subgroups consisting of multi-substance and MAP-only users, a significant difference was observed between these two groups in the tagging SNP, rs2910704, even after Bonferroni's correction (allele,  $P=0.034$ ). Multi-substance users in our study

primarily used organic solvents and marijuana in addition to MAP, and the mechanism of action of these drugs is different from that of MAP (Aoyama et al., 2006). In our current study, we observed that the MAF of rs2910704 in MAP-only users (0.47) was higher than that of multi-substance users (0.30), and a similar trend was seen for the age of first use. In other words, rs2910704 may be associated with the severity of substance dependency, as we detected association with earlier age of onset (Table 2) and multiple substance abuse (Table 3). Interestingly, we found a significant association with this SNP that differed between MAP-only users and normal controls, suggesting the involvement of this SNP in MAP dependence. Further, this SNP was in strong LD with rs11111 ( $r^2=1$ ), which is located 1.6 kb downstream of *GDNF* in the predicted 3'-UTR (ENCODE Gencode Manual Gene Annotations (level 1 + 2) (Feb., 2009)). The rs11111 SNP is associated with lower expression of *GDNF* in the brain but not in peripheral monoclonal blood cells as seen with SNPExpress (<http://people.genome.duke.edu/~dg48/SNPExpress/>) (Fig. 2,  $P=0.0026$ ). Thus, patients with these SNPs may exhibit lower expression of *GDNF* and be more vulnerable to MAP abuse. This hypothesis is consistent with a report showing that reduction in the expression of *GDNF* potentiates MAP self-administration and enhances motivation for mice to take MAP (Yan et al., 2007).

**Table 4**  
Genotype and allele frequencies of *GDNF* in the prognosis of psychosis.

No.	SNP ID	M/m	Group	N	Genotype			MAF	P value	
					M/M	M/m	m/m		Genotype	Allele
1	rs2973033 exon1	A/G	Transient	100	61	30	9	0.24	0.08	<b>0.02</b>
			Prolonged	75	33	31	11	0.35		
2	rs10941370 intron2	T/C	Transient	99	36	47	16	0.40	0.67	0.38
			Prolonged	75	31	35	9	0.35		
3	rs12518844 intron2	G/A	Transient	100	42	42	16	0.37	0.43	0.40
			Prolonged	75	33	35	7	0.33		
4	rs2910702 intron2	A/G	Transient	101	40	48	13	0.37	0.12	0.30
			Prolonged	75	31	41	3	0.31		
5	rs2910704 intron2	G/C	Transient	101	50	40	11	0.31	0.10	0.052
			Prolonged	75	25	39	11	0.41		
6	rs884344 intron2	A/C	Transient	100	66	31	3	0.19	0.37	0.16
			Prolonged	75	42	29	4	0.25		
7	rs1549250 intron2	G/T	Transient	100	47	39	14	0.34	0.17	0.27
			Prolonged	75	37	34	4	0.28		
8	rs2973049 intron2	G/A	Transient	100	26	50	24	0.49	0.39	0.76
			Prolonged	75	17	45	13	0.47		

Bold numbers represent significant P-values.

M: major allele and m: minor allele.

MAF: minor allele frequency.




Fig. 2. Relationship between *GDNF* expression in the frontal cortex of human brain and the rs11111 genotype.

In addition, other associated SNPs were in strong LD with rs2910704, and reduced expression of *GDNF* may therefore be implicated in the prognosis of MAP use disorder. Recently, Boger et al. (2007) suggested that long-term consequences of MAP exposure in mice are exacerbated in *GDNF* heterozygous mice, which may explain the significant association of these SNPs with age of onset or prognosis of MAP use disorder. This group also found elevated dopamine transporter (DAT) activity in *GDNF* heterozygous mice, suggesting that examination of DAT binding in our patients may be of interest.

Our results had several limitations in terms of interpreting positive associations. A potential concern was population admixture, which is a known confounding factor for association. The Japanese population has rather low genetic diversity (Haga et al., 2002). However, even in such a genetically homogeneous population, a small amount of stratification may produce a spurious genetic association signal (Yamaguchi-Kabata et al., 2008). Another potential concern is the relatively small sample size and that the gender ratio in the MAP group was not replicated in the control group. This type of discrepancy may introduce a gender-specific effect that could have resulted in inflated *p* values. Thus, larger numbers of gender-matched samples and genomic controls are required.

## 5. Conclusion

We suggest that *GDNF* may be related to the severity of MAP use. Further studies using independent replication will be required to clarify the relationship between *GDNF* and MAP use disorder.

## Acknowledgments

We thank the patients and healthy volunteers for their participation in our study. This work was supported in part by research grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, the Ministry of Health, Labor, and Welfare of Japan, a Grant-in-Aid for Scientific Research on Pathomechanisms of Brain Disorders from the Ministry of Education, Culture, Sports, Science and Technology of Japan, MEXT Academic Frontier, and the Core Research for Evolutional Science and Technology.

## References

Aoyama N, Takahashi N, Kitaichi K, Ishihara R, Saito S, Maeno N, et al. Association between gene polymorphisms of SLC22A3 and methamphetamine use disorder. *Alcohol Clin Exp Res* 2006;30(10):1644–9.

Balding DJ. A tutorial on statistical methods for population association studies. *Nat Rev Genet* 2006;7(10):781–91.

Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics* 2005;21(2):263–5.

Boger HA, Middaugh LD, Patrick KS, Ramamoorthy S, Denehy ED, Zhu H, et al. Long-term consequences of methamphetamine exposure in young adults are exacerbated in glial cell line-derived neurotrophic factor heterozygous mice. *J Neurosci* 2007;27(33):8816–25.

Carnicella S, Ron D. GDNF—a potential target to treat addiction. *Pharmacol Ther* 2009;122:9–18.

Carnicella S, Kharazia V, Jeanblanc J, Janak PH, Ron D. GDNF is a fast-acting potent inhibitor of alcohol consumption and relapse. *Proc Natl Acad Sci USA* 2008;105(23):8114–9.

Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. *Hum Hered* 2008;66(2):87–98.

Elkashaf A, Vocci F, Hanson G, White J, Wickes W, Tiitonen J. Pharmacotherapy of methamphetamine addiction: an update. *Subst Abus* 2008;29(3):31–49.

Freedman R. Schizophrenia. *N Engl J Med* 2003;349(18):1738–49.

Ghitza UE, Zhai H, Wu P, Airavaara M, Shaham Y, Lu L. Role of BDNF and GDNF in drug reward and relapse: a review. *Neurosci Biobehav Rev* 2010;35(2):157–71.

Green-Sadan T, Kinor N, Roth-Deri I, Geffen-Aricha R, Schindler CJ, Yadid G. Transplantation of glial cell line-derived neurotrophic factor-expressing cells into the striatum and nucleus accumbens attenuates acquisition of cocaine self-administration in rats. *Eur J Neurosci* 2003;18(7):2093–8.

Green-Sadan T, Kuttner Y, Lublin-Tennenbaum T, Kinor N, Boguslavsky Y, Margel S, et al. Glial cell line-derived neurotrophic factor-conjugated nanoparticles suppress acquisition of cocaine self-administration in rats. *Exp Neurol* 2005;194(1):97–105.

Grimm L, Holinski-Feder E, Teodoridis J, Scheffer B, Schindelbauer D, Meitinger T, et al. Analysis of the human *GDNF* gene reveals an inducible promoter, three exons, a triplet repeat within the 3′-UTR and alternative splice products. *Hum Mol Genet* 1998;7(12):1873–86.

Haga H, Yamada R, Ohnishi Y, Nakamura Y, Tanaka T. Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190,562 genetic variations in the human genome. Single-nucleotide polymorphism. *J Hum Genet* 2002;47(11):605–10.

Kendler KS, Gardner C, Jacobson KC, Neale MC, Prescott CA. Genetic and environmental influences on illicit drug use and tobacco use across birth cohorts. *Psychol Med* 2005;35(9):1349–56.

Kishi T, Tsunoka T, Ikeda M, Kitajima T, Kawashima K, Okochi T, et al. Serotonin 1A receptor gene is associated with Japanese methamphetamine-induced psychosis patients. *Neuropharmacology* 2010;58(2):452–6.

Kriegstein K, Suter-Crazzolaro C, Unsicker K. Development of mesencephalic dopaminergic neurons and the transforming growth factor-beta superfamily. *J Neural Transm Suppl* 1995;46:209–16.

Lee K, Kunugi H, Nanko S. Glial cell line-derived neurotrophic factor (*GDNF*) gene and schizophrenia: polymorphism screening and association analysis. *Psychiatry Res* 2001;104(1):11–7.

Lichtenstein P, Yip BH, Bjork C, Pawitan Y, Cannon TD, Sullivan PF, et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. *Lancet* 2009;373(9659):234–9.

Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. *Science* 1993;260(5111):1130–2.

Messer CJ, Eisch AJ, Carlezon Jr WA, Whisler K, Shen L, Wolf DH, et al. Role for GDNF in biochemical and behavioral adaptations to drugs of abuse. *Neuron* 2000;26(1):247–57.

Michelato A, Bonvicini C, Ventriglia M, Scassellati C, Randazzo R, Bignotti S, et al. 3′ UTR (AGG)<sub>n</sub> repeat of glial cell line-derived neurotrophic factor (*GDNF*) gene polymorphism in schizophrenia. *Neurosci Lett* 2003;357(3):235–7.

Morita Y, Ujike H, Tanaka Y, Uchida N, Nomura A, Ohtani K, et al. A nonsynonymous polymorphism in the human fatty acid amide hydrolase gene did not associate with either methamphetamine dependence or schizophrenia. *Neurosci Lett* 2005;376(3):182–7.

Nakama H, Chang L, Cloak C, Jiang C, Alicata D, Haning W. Association between psychiatric symptoms and craving in methamphetamine users. *Am J Addict* 2008;17(5):441–6.

Okochi T, Kishi T, Ikeda M, Kitajima T, Kinoshita Y, Kawashima K, et al. Genetic association analysis of NRG1 with methamphetamine-induced psychosis in a Japanese population. *Prog Neuropsychopharmacol Biol Psychiatry* 2009;33(5):903–5.

Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. *Bioinformatics* 2003;19(1):149–50.

Sato M, Numachi Y, Hamamura T. Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. *Schizophr Bull* 1992;18(1):115–22.

Wang J, Chen G, Lu B, Wu CP. GDNF acutely potentiates Ca<sup>2+</sup> channels and excitatory synaptic transmission in midbrain dopaminergic neurons. *Neurosignals* 2003;12(2):78–88.

Yamaguchi-Kabata Y, Nakazono K, Takahashi A, Saito S, Hosono N, Kubo M, et al. Japanese population structure, based on SNP genotypes from 7003 individuals compared to other ethnic groups: effects on population-based association studies. *Am J Hum Genet* 2008;83(4):445–56.

Yan Y, Yamada K, Niwa M, Nagai T, Nitta A, Nabeshima T. Enduring vulnerability to reinstatement of methamphetamine-seeking behavior in glial-cell-line-derived neurotrophic factor mutant mice. *FASEB J* 2007;21(9):1994–2004.

Yang F, Feng L, Zheng F, Johnson SW, Du J, Shen L, et al. GDNF acutely modulates excitability and A-type K(+) channels in midbrain dopaminergic neurons. *Nat Neurosci* 2001;4(11):1071–8.

Yui K, Ikemoto S, Ishiguro T, Goto K. Studies of amphetamine or methamphetamine psychosis in Japan: relation of methamphetamine psychosis to schizophrenia. *Ann NY Acad Sci* 2000;914:1–12.

(特集：認知機能障害に対する治療をどう評価するか)

## シンポジウム特集「認知機能障害に対する治療をどう評価するか」

曾 良 一 郎

東北大学大学院医学系研究科精神・神経生物学分野

統合失調症は陽性・陰性症状とともに記憶、遂行機能、注意、語流暢性など認知機能領域の障害を伴う。この認知機能障害は、精神病初回エピソードや顕在発症前の時点ですでに認められ、発症後も安定して存在することが知られている。また、認知機能障害は、社会適応や就労状況といった機能的転帰に影響し、長期的予後の予測因子にもなっている。以上から、認知機能障害は、統合失調症の中核症状の1つとして捉えられ、認知機能改善に向けた治療法の開発が望まれている。米国では、認知機能障害の治療法の開発を妨げていた認知機能評価尺度のばらつきを解消するため、信頼性・妥当性を有した包括的認知機能評価尺度である MATRICS コンセンサス認知機能評価バッテリー (MCCB) を用いることが可能になった。本邦でも諸外国と比較可能な MCCB 日本語版 (MCCB-J) を用いることにより、統合失調症の認知機能障害に対する治療を包括的に評価できるようになった。

新潟リハビリテーション大学の佐藤 拓先生は東北大学を中心として開発を行ってきた MCCB-J 下位検査のうち、本シンポジウムでは文化的・言語的な影響を受けやすいと予測されたマイヤー・サロヴェイ・カルーソー感情知能テスト：感情の管理 (MSCEIT ME) と言語的ワーキングメモリを測定する語音声列課題 (LNS) について紹介した。社会認知を測定するマイヤー・サロヴェイ・カルーソー感情知能テスト：感情の管理 (MSCEIT ME) は統合失調症患者および健常者を対象にした解析を行い、MSCEIT ME の妥当性・信頼性の検討を個別に行った。さらに、MCCB-J 全体の有効性を検討するため、統合失調症患者と健常者の認知機能の比較を行った結果を報告した。

統合失調症など精神疾患の認知機能障害に対する心理的手法として認知矯正療法があり、複数の手法が存在するが、鳥取大学の最上多美子先生は Medalia らが開発した Neurocognitive and Educational Approach to Remediation (NEAR) が認知機能障害の改善に一定の効果を示すことを紹介された。本シンポジウムでは認知矯正療法は訓練法の違い、訓練スキルの違い、媒体の違い、標的認知機能の違い、治療者の役割の違い、標的領域の違いなどにより異なり、RCT 研究で治療効果が示されている認知矯正療法的手法と効果について解説された。さらに認知矯正療法の効果に影響を与える要因としては、推奨された治療頻度の確保の重要性や戦略訓練が反復訓練に対して有効であることを示された。

認知機能の変化に加え、認知機能の評価尺度以上の表面的妥当性を持ち、機能的に意味がある co-primary な評価尺度の必要性が指摘されている。岩城クリニックの兼田康宏先生は、日常生活機能と直接関連する認知機能障害の程度を評価する目的で開発された統合失調症認知評価尺度 (Schizophrenia Cognition Rating Scale, SCoRS) の日本語版を作成された。SCoRS は University of California at San Diego Performance-Based Skills Assessment (UPSA) とともに米国 MATRICS アウトカム委員会により機能的に意味がある co-primary な評価尺度の候補として推薦されている。本シンポジウムでは認知機能との相関が強い UPSA と、面接に基づく認知機能評価尺度でより認容性/実用性に優れていた SCoRS について紹介された。

認知機能の障害の度合いは、心理社会的介入などの治療による就労への可能性や地域社会への適応度を予測し、患者の長期入院の必要性や就労の可否などの機能的転帰 (community functioning measures) と強く関連することが知られている。福島大学の住吉チカ先生は MCCB-J の開発に伴い、社会生活機能を測る方法として日本語版 Modified SFS/SAS (MATRICS-PASS 用) を作成された。日本語版 Modified SFS/SAS は、日本語版 SFS (根本, 2008) に沿いつつ、頻度・程度項目については英語版 Modified SFS/SAS 同様、アンカーポイントを設け、また基本的に自己記入式でも行えるよう作成された。本シンポジウムでは、機能的転帰の概念、評価方法、および各国への移植における問題について紹介された。

統合失調症患者の認知機能障害の特徴、機能的転機に深く関与する co-primary の評価、社会生活機能の3つの関連性を明らかにし、社会参加・就労の維持を目指した統合失調症患者へのより有効な治療・介入方法へつなげることが期待される。

[特集：認知機能障害に対する治療をどう評価するか]

## MATRICS コンセンサス認知機能評価バッテリー日本語版の開発への取り組み\*

佐藤 拓<sup>\*1</sup> 曾良 一郎<sup>\*2</sup><sup>\*1</sup>新潟県ハビリテーション大学医療学部<sup>\*2</sup>東北大学大学院医学系研究科精神・神経生物学分野

**要約：**統合失調症の認知機能障害は、就労への可能性やコミュニティへの適応度、長期入院の必要性などの機能的転帰を左右するとされ、認知機能改善に向けた治療が重視されている。米国では、国立精神保健研究所 (NIMH) 主導のもと、7つの認知機能領域 (処理速度、注意/覚醒、ワーキングメモリ、言語学習、視覚学習、推論と問題解決、社会認知) を測定する MATRICS コンセンサス認知機能評価バッテリー (MCCB) が開発された。MCCB の下位テストは、再テスト信頼性、繰り返し用いる評価尺度としての有用性、機能的転帰との関連性、および忍容性と実用性に優れたものから選定された実証的証拠のあるテストであった。MCCB は認知機能障害の改善薬の評価法の1つとして米国食品医薬品局 (FDA) に承認され、統合失調症の認知機能改善薬の治験における標準的な評価法として推奨されている。本邦への MCCB 導入は、アカデミックバージョンの日本語版の開発から始められた。本稿では、米国で開発された MCCB について概説した上で、研究用に開発された MCCB 日本語版の下位テストに関するパイロット研究の紹介を行った。

**キーワード：**MATRICS コンセンサス認知機能評価バッテリー (MCCB)、認知機能、日本語版、統合失調症

認知機能障害は統合失調症の中核症状の1つであり、多くの研究において機能的アウトカムとの関連が指摘されている (Green, 1996; Green et al, 2000, 2004a)。そのため、認知機能障害は精神薬理学における重要な治療ターゲットとしてみなされており (Marder and Fenton, 2004)、認知機能障害の改善に関する研究が盛んに行われている。

認知機能の改善を目指した薬物、もしくは心理社会的介入法の開発には、科学的なコンセンサスのとれた認知機能評価バッテリーを開発することが必須である。これまで、認知機能の評価には、認知の各領域を評価する検査を目的に応じて組み合わせた神経心理学的テストバッテリー (NTB) が用いられていたが、NTB は使用する研究者や施設間でのばらつきが大きく、得られた結果の比較が困難になっていた (兼田, 2009)。そのような現状を踏まえて、米国では国立精神保健研究所 (NIMH) が中心となり、米食品医薬品局 (FDA)、学界、製薬企業と共同で Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) と呼ばれるプロジェクトが企画された (Marder and Fenton, 2004)。このプロジェクトでは、統合失調症患者の認知機能改善薬の治験には不可欠な、科学的なコンセンサスを反映した NTB (MATRICS コンセンサス認知機能評価バッテリー; MCCB) の開発が行われた。

本稿では、まず米国で開発された MCCB について概説

した後、研究用に開発された MCCB 日本語版に関するパイロット研究について紹介する。

## MATRICS コンセンサス認知機能評価バッテリー (MCCB)

MCCB は、統合失調症で障害される認知機能領域を簡潔に評価するために開発された NTB である (Nuechterlein and Green, 2006)。MCCB に採用されたテストのほとんどは、従来から統合失調症の認知機能の測定に用いられているものであったが、下記のプロセスを経て選択および標準化された (Green et al, 2004b; Nuechterlein and Green, 2006)。

まず第1に、MCCB で評価される認知機能領域が決定された。MATRICS 神経認知委員会の小委員会が統合失調症と関連する精神疾患を対象とした研究のレビューを行い、そのレビューから7つの認知機能領域が同定された (Nuechterlein et al, 2004)。そのうちの1つである「言語理解」は、統合失調症においては障害が顕著ではないためにバッテリーから除かれ、残りの6つの領域が小委員会によって推薦された。この6つの領域に、近年、統合失調症の認知機能障害の領域として注目されている「社会認知」が加えられ (Kern et al, 2007)、MCCB では「処理速度」、「注意/覚醒」、「ワーキングメモリ」、「言語学習」、「視覚学習」、「推論と問題解決」、「社会認知」の7つの領域を評価することになった (Nuechterlein and Green, 2006)。

次に、7つの認知機能領域を評価する個々のテストを選択するための基準が決定された (Green et al, 2004b)。選択基準には (1) 再テスト信頼性、(2) 繰り返し用いる評価尺度としての有用性、(3) 機能的アウトカムとの関連性、(4) 薬物治療に対する反応性、(5) 忍容性と実用性が含め

\* 本論文は第40回日本神経精神薬理学会 (2010年9月、仙台) におけるシンポジウム講演の記録である。

<sup>\*1</sup> 〒958-0053 村上市上の山2-16

E-mail: t.sato@nur.ac.jp

(別刷請求先: 佐藤 拓)



られていたが、専門家が最も重視していた基準は再テスト信頼性であった (Kern et al, 2004). 上記の選択基準を満たす認知機能テストを選抜するために 90 以上のテストが推薦されたが、MATRICS 神経認知委員会は認知機能領域ごとにテストを絞り、20 のテストによって構成される  $\beta$  バッテリーを作成した (Nuechterlein and Green, 2006).

この  $\beta$  バッテリーから最終的なテストバッテリーを決定するため、176 人の統合失調症患者を対象とした MATRICS 心理測定・標準化研究 (MATRICS Psychometric and Standardization Study; MATRICS-PASS) が実施された (Nuechterlein et al, 2008). この研究で得られた結果と前述の選抜基準を鑑み、最終的なテストバッテリーに含めるテストが決定された。次に、MATRICS-PASS の第 2 段階として、採用されたテストがコミュニティから募った健常者 300 人に実施され、共通の規準データの収集が行われた (Kern et al, 2008).

上記のプロセスを経て開発された MCCB は、7 つの認知機能領域を測定する 10 のテストで構成されている。個々のテストの詳細については、Nuechterlein and Green (2006) による MCCB のマニュアルを参照されたい。MCCB の実施にかかる所要時間は約 65 分である (Nuechterlein et al, 2008). 個々のテストの T-score だけでなく、7 つの認知機能領域と総合的な認知機能の T-score を算出することができる。MCCB は認知機能障害の改善薬の評価法の 1 つとして FDA に承認され、統合失調症の認知機能改善薬の治験における標準的な評価法として推奨されている (Nuechterlein and Green, 2006).

#### MCCB 日本語版の開発とパイロット研究

MCCB はもともと英語版のみが利用可能であったが、現在は中国語、ドイツ語、ヒンディ語、ロシア語、スペイン語などに翻訳されている。本邦では曾良と兼田が中心となり、MATRICS Assessment, Inc. と各テストの原著者の許可を得た上で MCCB (アカデミックバージョン) の日本語への翻訳が行われた (兼田・曾良, 2009; 佐藤ら, 2010). 日本語版の開発にあたっては、ワーキングメモリの領域を測定する語音整列課題 (Gold et al, 1997) には言語的調整が必要であった。また、社会認知の領域を測定する Mayer-Salovey-Caruso 情動知能テスト：感情の管理 (Mayer et al, 2002) に関しては、得点化のための規準データが米国を中心とした欧米圏で集められているため、得点化に日本人の規準データを用いても原版と同様の結果が得られるかどうかを検討する必要があった。以下では、両テストについての概説、およびパイロット研究の紹介を行う。

##### 1. 語音整列課題

語音整列課題 (Letter-Number Span; LNS) は、数字および文字を昇順に並べ替える (例: 「J-5-T-2」→「2-5-

J-T」) 課題である (Gold et al, 1997). この課題の文字にはアルファベットが用いられていたため、日本語版では文字を日本人にとってなじみ深い五十音に変更する必要があった。住吉ら (2009) は、原版と文字・数字操作の課題負荷が同質になるように、また日本語における数字と五十音の発音、および五十音表の特性を考慮して日本語版を作成した。住吉らは統合失調症患者および健常者に、作成した日本語版とアルファベット版を同時に実施し、両課題の等価性を確認している。

##### 2. Mayer-Salovey-Caruso 情動知能テスト：感情の管理

Mayer-Salovey-Caruso 情動知能テスト (MSCEIT) は、Mayer et al (2002) が情動知能 (Emotional Intelligence; EI) の個人差を測定するために開発した能力モデルの尺度である。MSCEIT には情動知能に関する 4 つの下位尺度があるが、統合失調症患者を対象とした MATRICS-PASS では、部門 1: 感情の知覚 (Perceiving Emotions; PE) と部門 4: 感情の管理 (Managing Emotions; ME) が  $\beta$  バッテリーに含まれた (Nuechterlein and Green, 2006; Nuechterlein et al, 2008). MATRICS-PASS 研究において PE より ME の方が機能的アウトカムと関連が強いことから、最終的なバッテリーには ME が採択された (Nuechterlein and Green, 2006; Nuechterlein et al, 2008).

MSCEIT ME は、セクション D と H の 2 つの課題から構成されている (Mayer et al, 2002). セクション D では、自己の感情を意思決定に組み込む能力を測定する。この課題では、感情を制御しなければならない状況下で、ある結果を得るために選択肢の行動がどの程度有効であるかを回答者に評価させる。セクション H では、他者が関わる意思決定に感情を組み込む能力を測定する。この課題では、他者が関わる状況において、ある結果を得るためにはどの行動が効果的であるかを回答者に評価させる。どちらの課題も回答者にシナリオを提示して、そのシナリオの状況下で、ある行動がどの程度効果的であるかを評価させる課題である。

上記の課題で得られた回答を採点する方法として、2 つの採点方法がある (Mayer et al, 2002). 1 つ目は一般的コンセンサスによる採点方法であり、各項目への反応を採点するために、規準データにおける回答分布を利用する。この方法では、ある項目に対して規準となるサンプルの 70 % が A を選択していたら、A の反応に対して 70 の得点が与えられる。もし B を 20 % が選択していたら、B への反応は 20 の得点が与えられる。もう 1 つは専門家のコンセンサスによる採点方法であり、規準データの代わりに 21 名の感情研究の専門家のサンプルのデータを用いる。MCCB では 2 つの採点方法のうち、一般的コンセンサスによる方法が採用されている (Nuechterlein and Green, 2006).

Mayer et al (2002) の原版では、5,000 人のデータを米国の人口分布に合わせて重みづけた規準データを用いている。このデータを用いて日本語版の得点化を行うことも可能であるが、同質な集団の規準データを用いる方が文化的な交絡を最小化することができる (Roberts et al, 2006)。そのため、オーストラリア人の規準データによって得点化した Roberts et al (2006) と同様、我々は得点化に本邦の規準データを用いることにした。

佐藤ら (2009) は MSCEIT 日本語版のパイロット研究として、大学生を対象者に規準データの収集を行った。284 名の回答を基準データとして、各参加者の得点を一般的コンセンサスによる採点方法で算出したところ、その平均値 ( $M=.32, SD=.04$ ) は原版 (Mayer et al, 2002) の平均値 ( $M=.45, SD=.08$ ) と比べると低かった。つまり、本邦の大学生のデータでは、原版に比べると大多数の回答が 1 つの選択肢に収束しなかったと考えられる。ただし、ここで得られた平均値は、スペイン語版を作成した Extremera et al (2006) の平均値 ( $M=.33, SD=.09$ ) と同程度であることを付記しておく。

次に MSCEIT ME の得点の性差を検討したところ、男性の得点 ( $M=.31, SD=.04$ ) より女性 ( $M=.33, SD=.03$ ) の得点が高かった ( $t=4.67, p<.001, \text{Cohen's } d=0.56$ )。この結果は、原版の Mayer et al (2002) の結果、およびスペイン語版を検討した Extremera et al (2006) の結果と一致している。

また、上記のデータのうち 128 名は、5 因子パーソナリティ検査である NEO-FFI 日本語版 (下仲ら, 1999) を同時に評定していた。MSCEIT ME の得点と NEO-FFI の下位尺度の相関係数を算出したところ、調和性とのみ有意な正の相関が確認された ( $r=.23, p<.01$ )。調和性は利他性・共感性に関連するパーソナリティ傾向であるため、5 因子の中で調和性との相関が最も強い結果は予測通りと言えた。ただし、その相関係数の絶対値は小さく、Mayer et al (2004) のレビューで示された結果とほぼ同値であった (表)。Mayer et al (2004) はこの結果から、MSCEIT はパーソナリティと別個の概念を測定していると主張している。本邦でも 5 因子パーソナリティ傾向との相関係数が低いことから、日本語版もパーソナリティとは別個の概念を測定していると考えられる。

さらに、Sato et al (2010) は、統合失調症患者 20 名と健常者 10 名を対象に、前述の規準データで重みづけた

MSCEIT ME 得点の比較を行った (図)。その結果、統合失調症患者の得点 ( $M=.29, SD=.03$ ) は健常者の得点 ( $M=.33, SD=.04$ ) に比べて低いことが確認された ( $t=-2.65, p<.05, \text{Cohen's } d=1.02$ )。この結果は、原版の MSCEIT ME を用いて統合失調症の社会認知を検討した研究 (Kee et al, 2009; Eack et al, 2010) に合致するものであった。

以上のように、パイロット研究では原版を用いた先行研究に合致する結果が得られている。ただし、これらの研究で用いられた規準データは大学生のサンプルで構成されている。一般的コンセンサスを利用した MSCEIT ME の得点は、規準データの質によって直接的に左右されるため、本邦でも大規模な規準データを収集したうえで、統合失調症患者を対象とした MSCEIT ME の再テスト信頼性、および機能的アウトカムと関連性を検討する必要がある。

### おわりに

本稿では、米国で開発された MCCB の概説、および研究用に開発された MCCB 日本語版のパイロット研究の紹介を行った。紹介したパイロット研究は個々のテスト (LNS および MSCEIT ME) についての検討であったが、曾良を中心とする研究グループでは研究用の MCCB を用いて統合失調症患者および健常者のデータを集積し、日本語版の信頼性、妥当性、および機能的アウトカムとの関連性の検討を進めている。また、(財)精神・神経科学振興財団の主導で MCCB 日本語版の標準化研究も 2009 年にスタートしている。これらの研究をもとに最終的な MCCB 日本語版が完成すれば、本邦での認知機能の改善を目指した薬




図 統合失調症患者と健常者の MSCEIT ME 得点の比較 (Sato et al, 2010 より)。

表 MSCEIT ME 得点と 5 因子パーソナリティ傾向の相関

	神経症傾向	外向性	開放性	調和性	誠実性
佐藤ら (2009)	.01	.08	.15	.23**	-.03
Mayer et al (2004)	-.07**	.11***	.15***	.24***	.13***

注) Mayer et al (2004) の相関係数は、MSCEIT および MEIS と 5 因子パーソナリティ傾向との相関を報告した 5 つの研究 ( $N=1,584$ ) で得られた相関係数を重みづけた平均値である。\*\* $p<.01$ , \*\*\* $p<.005$

物や心理社会的介入法の開発がより一層促進されるであろう。

シンポジウム発表の機会をくださった鳥取大学 中込和幸先生 (現: (独)国立精神・神経医療研究センター)、本稿で紹介したパイロット研究の共同研究者である岩城クリニック 兼田康宏先生、富山大学 住吉太幹先生、西山志満子先生、福島大学 住吉チカ先生、発表に関してご助力いただきました東北大学 宮澤志保先生、東海林渉先生に感謝申し上げます。本稿で紹介した研究の一部は、厚生労働科学研究費補助金「統合失調症における社会生活機能障害の評価・支援—MATRICS-CCB 日本語版による認知機能障害の評価と治療計画への応用—(H21-こころ-一般-003)」における研究に基づく。

## 文 献

- Eack, S. M., Greeno, C. G., Pogue-Geile, M. F., Newhill, C. E., Hogarty, G. E. and Keshavan, M. S. (2010) Assessing social-cognitive deficits in schizophrenia with the Mayer-Salovey-Caruso Emotional Intelligence Test. *Schizophr Bull*, 36: 370-380.
- Extremera, N., Fernandez-Berrocal, P. and Salovey, P. (2006) Spanish version of the Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT). Version 2.0: Reliabilities, age and gender differences. *Psicothema*, 18 [Suppl]: 42-48.
- Gold, J. M., Carpenter, C., Randolph, C., Goldberg, T. E. and Weinberger, D. R. (1997) Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. *Arch Gen Psychiatry*, 54: 159-165.
- Green, M. F. (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? *Am J Psychiatry*, 153: 321-330.
- Green, M. F., Kern, R. S., Braff, D. L. and Mintz, J. (2000) Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff"? *Schizophr Bull*, 26: 119-136.
- Green, M. F., Kern, R. S. and Heaton, R. K. (2004a) Longitudinal studies of cognition and functional outcome in schizophrenia: Implications for MATRICS. *Schizophr Res*, 72: 41-51.
- Green, M. F., Nuechterlein, K. H., Gold, J. M., Barch, D. M., Cohen, J., Essock, S., Fenton, W. S., Frese, F., Goldberg, T. E., Heaton, R. K., Keefe, R. S., Kern, R. S., Kraemer, H., Stover, E., Weinberger, D. R., Zalcman, S. and Marder, S. R. (2004b) Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria. *Biol Psychiatry*, 56: 301-307.
- 兼田康宏 (2009) VII. 広認知機能と QOL・社会機能評価。精神疾患と認知機能研究会 (編) 精神疾患と認知機能。新興医学出版社, 東京, pp163-167.
- 兼田康宏, 曾良一郎 (2009) MATRICS 認知機能評価バッテリー (MCCB) 日本語版の開発。第 4 回日本統合失調症学会, 大阪。
- Kee, K. S., Horan, W. P., Salovey, P., Kern, R. S., Sergi, M. J., Fiske, A. P., Lee, J., Subotnik, K. L., Nuechterlein, K., Sugar, C. A. and Green, M. F. (2009) Emotional intelligence in schizophrenia. *Schizophr Res*, 107: 61-68.
- Kern, R. S., Green, M. F., Nuechterlein, K. H. and Deng, B. H. (2004) NIMH-MATRICS survey on assessment of neurocognition in schizophrenia. *Schizophr Res*, 72: 11-19.
- Kern, R. S., Green, M. F. and Marder, S. R. (2007) The NIMH MATRICS initiative: Development of a consensus cognitive battery. *Prog Neurother Neuropsychopharmacol*, 2: 173-186.
- Kern, R. S., Nuechterlein, K. H., Green, M. F., Baade, L. E., Fenton, W. S., Gold, J. M., Keefe, R. S., Mesholam-Gately, R., Mintz, J., Seidman, L. J., Stover, E. and Marder, S. R. (2008) The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. *Am J Psychiatry*, 165: 214-220.
- Marder, S. R. and Fenton, W. (2004) Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia. *Schizophr Res*, 72: 5-9.
- Mayer, J. D., Salovey, P. and Caruso, D. R. (2002) Mayer-Salovey-Caruso Emotional Intelligence Test. Toronto: MHS Publishers.
- Mayer, J. D., Salovey, P. and Caruso, D. R. (2004) Emotional intelligence: Theory, findings, and implications. *Psychol Inq*, 15: 197-215.
- Nuechterlein, K. H., Barch, D. M., Gold, J. M., Goldberg, T. E., Green, M. F. and Heaton, R. K. (2004) Identification of separable cognitive factors in schizophrenia. *Schizophr Res*, 72: 29-39.
- Nuechterlein, K. H. and Green, M. F. (2006) MATRICS Consensus Cognitive Battery. Los Angeles: MATRICS Assessment, Inc.
- Nuechterlein, K. H., Green, M. F., Kern, R. S., Baade, L. E., Barch, D. M., Cohen, J. D., Essock, S., Fenton, W. S., Frese III, F. J., Gold, J. M., Goldberg, T., Heaton, R. K., Keefe, R. S., Kraemer, H., Mesholam-Gately, R., Seidman, L. J., Stover, E., Weinberger, D. R., Young, A. S., Zalcman, S. and Marder, S. R. (2008) The MATRICS Consensus Cognitive Battery, part 1: Test selection, reliability, and validity. *Am J Psychiatry*, 165: 203-213.
- Roberts, R. D., Schulze, R., O'Brien, K., MacCann, C., Reid, J. and Maul, A. (2006) Exploring the validity of the Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) with established emotions measures. *Emotion*, 6: 663-669.
- Sato, T., Shoji, W., Kaneda, Y., Sumiyoshi, C., Sumiyoshi, T. and Sora, I. (2010) Development of MATRICS Consensus Cognitive Battery Japanese version (MCCB-J). Paper presented at the Tohoku University-Taiwan Neuroscience Workshop for Young Scientists, Yi-Lan.
- 佐藤 拓, 兼田康宏, 住吉チカ, 住吉太幹, 曾良一郎 (2009) Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) 検査バッテリー日本語版の開発。第 19 回日本臨床精神神経薬理学会・第 39 回日本神経精神薬理学会合同年会, 京都。
- 佐藤 拓, 兼田康宏, 住吉チカ, 住吉太幹, 曾良一郎 (2010) MATRICS コンセンサス認知機能評価バッテリーの開発: 統合失調症治療への導入を目指して。臨精薬理, 13: 289-296。
- 下仲順子・中里克治・榎藤恭之・高山 緑 (1999) NEO-PI-R/NEO-FFI 日本版共通マニュアル。東京心理, 東京。
- 住吉チカ, 住吉太幹, 兼田康宏, 佐藤 拓, 西山志満子, 曾良一郎 (2009) MATRICS コンセンサス認知機能評価バッテリー日本語版の開発: 語音整列課題における使用言語の影響。第 5 回日本統合失調症学会, 福岡。

**Abstract:** Taku SATO\*<sup>1</sup> and Ichiro SORA\*<sup>2</sup> (\*<sup>1</sup> Faculty of Allied Health Science, Niigata University of Rehabilitation, 2-16 Kamino-Yama, Murakami, 958-0053 Japan; \*<sup>2</sup> Department of Biological Psychiatry, Tohoku University Graduate School of Medicine) *Approaches to the development of the Japanese academic version of the MATRICS Consensus Cognitive Battery*. *Jpn. J. Neuropsychopharmacol.*, 31: 241-244 (2011).

Cognitive impairment is related to functional outcome (e.g., work skills and community activities) in patients with schizophrenia; therefore, many researchers view these impairments as important treatment targets for psychopharmacological treatment. To stimulate the development of new treatments for cognitive impairments, the US National Institute of Mental Health's (NIMH's) Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative developed a standard cognitive battery, i.e., the MATRICS Consensus Cognitive Battery (MCCB). In Japan, the MCCB has been initially translated as an academic version. This paper describes the process of developing the Japanese academic version and focuses on pilot studies on subtests of this battery.

**Key words:** MATRICS Consensus Cognitive Battery (MCCB), Cognitive function, Japanese version, Schizophrenia

(Reprint requests should be sent to T. Sato)

**REVIEW****Quality of life and its predictors in people with schizophrenia**

Masahito Tomotake

*Department of Mental Health, Institute of Health Biosciences, the University of Tokushima Graduate School, Tokushima, Japan*

**Abstract :** The author reviewed measurement of quality of life (QOL) of schizophrenia patients and the clinical factors related to their QOL. As schizophrenia patients were thought to be unable to assess their own QOL because of their cognitive impairment, objective QOL measures had been frequently used. However, nowadays, there is general agreement that symptomatically stabilized patients could assess their QOL by themselves. Therefore, researchers gradually have become interested in subjective QOL measure. Although most researchers often evaluate schizophrenia patients' QOL using only subjective or objective QOL measure, considering the fact that there is a discrepancy between the two types of measures, it is recommended to use both of them as complementary measures. As for clinical factors related to lowered QOL, several studies reported that depressive symptom was most associated with lowered subjective QOL, negative symptom was strongly related to lowered objective one and poor life skill was associated with both. Moreover, several studies found that cognitive dysfunctions in some cognitive domains were related to lowered objective QOL but the effects of them were much smaller than those of negative symptoms. It is suggested that improving depressive and negative symptoms and life skills may contribute to enhancement of QOL of schizophrenia patients. *J. Med. Invest.* 58 : 167-174, August, 2011

**Keywords :** schizophrenia, quality of life, life skill, cognitive function

**INTRODUCTION**

Schizophrenia is a disease that can devastate the lives of people who suffer from it, and people with it suffer distress, disability, reduced productivity, and lowered quality of life (QOL). Over the past two decades, the concept of QOL has become an important attribute in patient care and research in psychiatry area (1-3).

---

Received for publication April 21, 2011 ; accepted April 28, 2011.

Address correspondence and reprint requests to Masahito Tomotake, M.D., Ph.D., Department of Mental Health, Institute of Health Biosciences, the University of Tokushima Graduate School, Kuramoto-cho, Tokushima 770-8503, Japan and Fax : +81-88-633-9083.

Although there seems to be no unanimous definition of QOL at the moment, there is general agreement that QOL consists of access to resources and opportunities, fulfillment of life's roles, level of functioning and a sense of well being or life satisfaction (4, 5). As QOL is today regarded one of the most important outcome measures, it is important to clarify the clinical factors associated with lowered QOL. Doing so can lead to more sophisticated treatment strategies.

In this article, the author reviewed some existing articles on measurement of QOL of schizophrenia patients and clinical factors associated with QOL.

## MEASUREMENT OF QUALITY OF LIFE

Recently, there has been increasing interest in QOL of people with schizophrenia, and now, QOL measures are included routinely in most studies of intervention or outcome (5, 6). However, not a few problems have been identified with the implement of the instruments. Such problems include the definition of the concept of QOL and the approach for measurement of it. Although there is no unanimous definition of QOL, the World Health Organization defines QOL as individuals' perception of their position in life in the context of culture and value systems in which they live and in relation to their goals, expectations, standards, and concerns (7).

QOL of people with schizophrenia has been measured from two different viewpoints. One is a self-rated measurement of QOL (subjective QOL) and the other is an interviewer-rated measurement of QOL (objective QOL). Although, according the definition by the World Health Organization, individuals' perception of QOL seems to be vital, QOL of schizophrenia patients had been frequently assessed with objective QOL measures. Because of schizophrenia patients' cognitive impairment, they had been thought to be unable to evaluate their own QOL by themselves. However, nowadays, there is general agreement that stabilized schizophrenia patients could assess their QOL by themselves (8).

Objective measures of QOL usually include indicators of health and living conditions, sociodemographic items and role functioning in society, whereas subjective measures of QOL do indicators of life satisfaction in general and within different life domains (5). For example, the Quality of Life Scale (QLS) (9), one of the most frequently used objective QOL measures, was specifically constructed to measure QOL of people with schizophrenia. The QLS is a 21-item scale from a semistructured interview providing information on symptoms and functioning during the preceding 4 weeks. The QLS has four subscales, Intrapsychic foundations, Interpersonal relations, Instrumental role, and Common objects and activities. Intrapsychic foundations subscale items elicit judgments about intrapsychic elements in the dimensions of cognition, conation, and affectivity seen as near the core deficit of schizophrenia. Interpersonal relations subscale relates to various aspects of interpersonal and social experience. Instrumental role subscale focuses on the role of worker, student, or housekeeper/parent. Common objects and activities subscale is based on the assumption

that a robust participation in the community is reflected in the possession of common objects and the engagement in regular activities (9).

As for subjective QOL instruments, although not a few subjective QOL instruments exist to assess health-related QOL, it is said that they can sometimes overlook the QOL concerns of specific patients groups. Recently, Wilkison *et al.* (10) constructed schizophrenia disease specific subjective QOL instrument that is called the Schizophrenia Quality of Life Scale (SQLS). The SQLS consists of three scales that are Psychosocial, Motivation and energy, and Symptoms and side-effect. Lower scores indicate higher QOL. The Japanese version of it is often used in studies in Japan (11).

## RELATION BETWEEN SUBJECTIVE AND OBJECTIVE QUALITY OF LIFE MEASURES

Researchers have been paying attention to the relation between subjective and objective QOL measures. Although many studies used only one of them, if they reflect different aspects of QOL and have different predictors, doing so is likely to introduce bias in the results. However, there are only a few studies investigating the relation between them.

Using the Quality of Life Interview which contains subjective and objective measures, Dickerson *et al.* (12) studied 72 outpatients with schizophrenia and demonstrated that there were few significant correlations between subjective and objective QOL indicators of specific life areas. Fitzgerald *et al.* (5) found that life satisfaction and objectively rated QOL are not closely related, and concluded that subjective and objective QOL had different determinants in patients with schizophrenia.

To explore the relationship between subjective and objective QOL measures, we conducted a strict research using schizophrenia disease specific subjective and objective QOL measures (13). In the cross-sectional study, 99 symptomatically stabilized outpatients with a DSM-IV diagnosis of schizophrenia were assessed with the SQLS (10, 11) and the QLS (9). The correlations between the scores on scales of the SQLS and the QLS total and subscales in the study are shown in Table 1. The score of the Motivation and energy scale correlated significantly with the QLS total score, Interpersonal relations, Instrumental role, Intrapsychic foundations, and Common Objects and activities subscales. Moreover, the score of the Psychosocial scale showed a

Table 1 Correlation between Schizophrenia Quality of Life Scale and Quality of Life Scale (N=99) (from Ref.13 Tomotake M, *et al.* Psychol Rep 99, 477-487, 2006)

	SQLS		
	Psychosocial	Motivation and energy	Symptoms and side- effects
QLS Total	-.20 *	-.40 ***	-.16
Interpersonal relations	-.19	-.42 ***	-.16
Instrumental role	-.19	-.28 **	-.14
Intrapsychic foundations	-.19	-.39 ***	-.14
Common objects and activities	-.10	-.25 *	-.14

\*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .

SQLS=Schizophrenia Quality of Life Scale, QLS=Quality of Life Scale.

significant but weak correlation with the QLS total score. The score of the Symptoms and side-effects scale did not correlate significantly with the QLS scores.

Considering these results indicating that there were only a few significant correlations between the SQLS and the QLS scores, researchers should use both of subjective and objective QOL measures as complementary outcome measures in order to avoid introducing bias.

## RELATION BETWEEN CLINICAL SYMPTOMS AND QUALITY OF LIFE

As for the clinical symptoms associated with subjective QOL, Dickerson *et al.* (1998) found that schizophrenia patients' subjective QOL measured by the Quality of Life Interview was significantly related to the depression factor in the Positive and Negative Syndrome Scale (PANSS). Huppert *et al.* (14) also found that more severe depression as rated on the Brief Psychiatric Rating Scale (BPRS) was associated with lower subjective QOL measured by the Quality of Life Interview. Other similar studies support the significant association of depressive symptom with subjective QOL (5, 15). As for subjective well-being which is the main component of subjective QOL, Norman *et al.* (16) reported that the General Well-Being Scale score was significantly related to positive symptom, particularly reality distortion. These results suggest that depressive and positive symptoms may be important factors influencing schizophrenia patients' subjective QOL. Moreover, other clinical factors such as anxiety, extrapyramidal adverse effects, and patients' subjective responses and attitudes towards antipsychotic treatment have been found to be significantly associated with subjective QOL (1, 14, 15).

Clinical factors related to objective QOL also have been investigated, and several research groups reported that negative symptom was much more closely related to objective QOL than was positive symptom (5, 16). As the studies used the QLS which was originally designed to assess deficit symptoms of schizophrenia, it may stand to reason that fewer negative symptoms were associated with better QOL assessed by the QLS. However, some studies showed the significant associations of positive symptom and other clinical factors with the QLS (17-20).

We investigated the relationship between several clinical factors (duration of illness, number of hospitalization, dose of neuroleptics, positive symptom, negative symptom, extrapyramidal symptom, and depressive symptom) and QOL in outpatients with schizophrenia (13). The results of stepwise regression analyses on the SQLS and the QLS in the study are shown in Table 2. Psychosocial scale score was predicted independently by the Calgary Depression Scale for Schizophrenia (CDSS) score, the BPRS positive symptoms score, dose of neuroleptics, and the BPRS negative symptoms score. The CDSS score contributed significantly to the prediction of the Motivation and energy scale score. Symptoms and side-effects scale score was predicted independently by the BPRS positive symptoms score, the CDSS score, and dose of neuroleptics. The QLS total score was predicted independently by the BPRS negative symptoms score and the BPRS positive symptoms score. The BPRS negative symptoms score and duration of illness contributed independently to the prediction of the Interpersonal relations subscale. Instrumental role subscale was predicted independently by the BPRS negative symptoms score and the BPRS positive symptoms score. The Intrapsychic foundations subscale was also predicted by the BPRS negative symptoms score and the

Table 2 Summary of stepwise regression analyses on Schizophrenia Quality of Life Scale and Quality of Life Scale (N=99) (from Ref.13 Tomotake M, *et al. Psychol Rep* 99, 477-487, 2006)

Dependent variables		Independent variables	Adjusted R <sup>2</sup>	$\beta$
SQLS Psychosocial		CDSS	.48***	.58***
		BPRS positive symptoms		.42***
		Dose of neuroleptics		-.22**
		BPRS negative Symptoms		-.18*
Motivation and energy	CDSS	.23***	.48***	
Symptoms and side-effects		BPRS positive symptoms	.21***	.37**
		CDSS		.27**
		Dose of neuroleptics		-.20*
QLS Total		BPRS negative symptoms	.46***	-.53***
		BPRS positive symptoms		-.24**
Interpersonal relations		BPRS negative symptoms	.36***	-.60***
		Duration of illness		-.21*
Instrumental role		BPRS negative symptoms	.28***	-.33**
		BPRS positive symptoms		-.31**
Intrapsychic foundations		BPRS negative symptoms	.53***	-.59***
		BPRS positive symptoms		-.24**
Common objects and activities		BPRS negative symptoms	.33***	-.58***
		Duration of illness		-.19*

\*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .

SQLS=Schizophrenia Quality of Life Scale, QLS=Quality of Life Scale, CDSS=Calgary Depression Scale for Schizophrenia, BPRS= Brief Psychiatric Rating Scale.

BPRS positive symptoms score. The BPRS negative symptoms score and duration of illness contributed independently to the prediction of the Common objects and activities subscale.

In general, these findings seem to indicate that depressive symptom is the most important predictor of subjective QOL and negative symptom is the most important one of objective QOL.

## RELATION BETWEEN LIFE SKILLS AND QUALITY OF LIFE

There are a few studies that investigated the relationship between life skill and QOL in people with schizophrenia. Norman *et al.* (16) reported the significant relationships among life skill, subjective QOL and objective QOL in subjects with schizophrenia or schizoaffective disorder. On the other hand,

Parker *et al.* (21) reported no significant correlation between life skill and subjective QOL.

Recently, Aki *et al.* (22) investigated the relation between life skills and QOL in schizophrenia patients. In the study, they used the Life Skills Profile (LSP) to evaluate life skills of patients with schizophrenia, and subjective QOL and objective QOL were assessed the SQLS and the QLS, respectively. The LSP was designed by Rosen *et al.* (23) to assess survival and adaptation in the community by individuals with severe mental illness. The LSP is a thirty nine-item questionnaire. Each item is rated from 1 to 4 and a higher score indicates a greater level of life skills. The LSP has five subscales that are Self-care, Non-turbulence, Socialization, Communication, and Responsibility. Table 3 shows the results of correlation analyses between the SQLS, the QLS and the LSP in the study. The LSP total score correlated with scores of the SQLS and the

Table 3 Correlation among Schizophrenia Quality of Life Scale, Quality of Life Scale and Life Skills Profile (N=64) (from Ref.22 Aki H, *et al.* Psychiatry Res 158, 19-25, 2008)

	SQLS			QLS				
	Psychosocial	Motivation and energy	Symptoms and side-effects	Total	Interpersonal relations	Instrumental role	Intrapsychic foundation	Common objects and activities
<b>LSP</b>								
Total	-0.47**	-0.41*	-0.46**	0.55**	0.48**	0.56**	0.49**	0.47**
Self-care	-0.40*	-0.32	-0.43**	0.52**	0.46**	0.54**	0.45**	0.49**
Non-turbulence	-0.44**	-0.25	-0.43**	0.16	0.08	0.24	0.17	0.13
Socialization	-0.36	-0.44**	-0.28	0.63**	0.57**	0.57**	0.57**	0.50**
Communication	-0.33	-0.31	-0.37*	0.37	0.32	0.39*	0.33	0.27
Responsibility	-0.24	-0.17	-0.25	0.26	0.22	0.29	0.23	0.26

\* $p < 0.05$ , \*\* $p < 0.01$  (Bonferroni correction).

SQLS=Schizophrenia Quality of Life Scale, QLS=Quality of Life Scale, LSP=Life Skills Profile.

QLS, which seems to indicate that basic life skills have some effects on schizophrenia patients' QOL. Especially, life skills about self-care and socialization are important factors.

From the findings, it is suggested that improving life skills may lead to enhancement of schizophrenia patients' QOL. However, a prospective research will be needed to clarify this.

## RELATION BETWEEN COGNITIVE FUNCTION AND QUALITY OF LIFE

Cognitive problems have been considered a core component of schizophrenia. However, they have only recently been considered as potential treatment targets (24). Recently, it has become apparent that there are several aspects of impaired neurocognition that are consistently found in schizophrenia. Such cognitive dysfunctions are paid much more attention because they are thought to lead to poor social functioning.

Some research groups reported that functional magnetic resonance imaging (fMRI), positron emission tomography (PET), and electroencephalogram (EEG) show relations between neuroanatomical measures and cognitive deficits in schizophrenia patients, and these relations are particularly found in frontal regions, temporal cortex, and hippocampus (24). And it has been reported that cognitive functions of schizophrenia patients were of the order of one to two standard deviations below the mean of healthy controls in several cognitive dimensions, particularly memory, attention, verbal fluency, and executive function (25-28).

These cognitive dysfunctions are thought to be associated with lowered social activity, poor acquisition of social skills during the rehabilitation programme, and lowered QOL. Some previous research groups have investigated the relation between QOL and cognitive function in people with schizophrenia, and reported the significant correlations between QOL and some domains of cognitive function such as verbal memory, vocabulary, fluency performance, attention, social knowledge, and executive function (12, 28, 29-32).

From the results of previous studies, it seems to be clear that cognitive dysfunctions and some clinical symptoms are significantly correlated with lowered QOL in schizophrenia patients. However, it remains unclear how much impact these factors have on their QOL. Some studies demonstrated that cognitive dysfunction had a greater influence on schizophrenia patients' QOL than positive symptoms (33-35). On the other hand, some reported that neuropsychological function had a little impact on their QOL in the presence of some clinical symptoms (32, 36). The discrepancy among these studies might have been caused by differences of sample population, cognitive tests, and QOL scales (32-34, 36).

To elucidate the relation between cognitive function and QOL in schizophrenia patients, Yamauchi *et al.* (37) investigated the relations between the SQLS, the QLS, and the PANSS cognitive factor in 84 outpatients with schizophrenia. The results showed that although the PANSS cognitive factor was significantly correlated with both of the SQLS and the QLS, it seemed to have a greater influence on the QLS score than the SQLS score.

Recently, our research group (38) conducted a



strict study to elucidate the relation between cognitive function and QOL by using the Brief Assessment of Cognition in Schizophrenia (BACS) (39, 40) that is a newly developed neuropsychological battery for assessing cognitive function of schizophrenia patient. The BACS has been developed for clinical trials with a brief battery of tests for measuring cognition. It assesses the aspects of cognition that were found to be most impaired and most strongly correlated with outcome in patients with schizophrenia. The domains of cognitive function evaluated by the BACS are Verbal memory (List learning), Working memory (Digit sequencing task), Motor speed (Token motor task), Verbal fluency (Category instances and Controlled oral word association test), Attention and speed of information processing (Symbol coding), and Executive function (Tower of London) (39).

In our study (40), Z-score for Verbal memory was -1.68 (SD=1.28), that for Working memory -1.23 (SD=1.78), that for Motor speed -1.81 (SD=1.64), that for Attention and speed of information processing -1.66 (SD=1.19), that for Verbal fluency -0.82 (SD=1.11), and that for Executive function -1.20 (SD=1.95), showing that cognitive performance of schizophrenia patients were much disturbed than healthy controls. The correlations between the QLS scores and the BACS scores are shown in Table 4. The BACS Composite score, Attention and speed of information processing score, and Verbal memory score showed significant and positive correlations with the QLS total and all or some subscale scores. In the study, stepwise regression analyses when using several clinical variables including the BACS scores as independent variables showed that

the QLS total score was significantly predicted by the PANSS negative syndrome scale score, the CDSS score, and the BACS Attention and speed of information processing score. The results were rather consistent with those of previous researches in terms of that cognitive dysfunction was on the whole related to lowered objective QOL (28, 30, 37).

In addition, we also investigated the relation between subjective QOL and cognitive function and reported that there was no significant correlation between them (41).

## CONCLUSIONS

Subjective and objective QOL measures have different predictors in people with schizophrenia. Depressive symptom is most related to subjective QOL, negative symptom is most associated with objective one, and basic life skills are related to both. Cognitive dysfunctions in some neurocognitive domains are associated with lowered objective QOL, but the effects of them are much smaller than negative and depressive symptoms. It is suggested that improving depressive and negative symptoms and basic life skills may contribute to enhancement of QOL of schizophrenia patients.

## REFERENCES

1. Awad AG, Voruganti LN, Heslegrave RJ : A conceptual model of quality of life in schizophrenia : description and preliminary clinical validation. *Qual Life Res* 6 : 21-26, 1997

Table 4 Correlation between Quality of Life Scale and Brief Assessment of Cognition in Schizophrenia (N=61) (from Ref.38 Ueoka Y, *et al.* *Prog Neuropsychopharmacol Biol Psychiatry* 35, 53-59, 2011)

	QLS				
	Total	Interpersonal relations	Instrumental role	Intrapsychic foundation	Common objects and activities
<b>BACS</b>					
Verbal memory	0.419**	0.415**	0.311	0.422**	0.295
Working memory	0.281	0.283	0.142	0.290	0.259
Motor speed	0.196	0.175	0.126	0.222	0.228
Attention and speed of information processing	0.515**	0.495**	0.372*	0.541**	0.418**
Verbal fluency	0.203	0.200	0.154	0.206	0.170
Executive function	0.168	0.174	0.103	0.131	0.175
Composite score	0.341*	0.346*	0.205	0.341*	0.305

\* $p < 0.05$ , \*\* $p < 0.01$  (Bonferroni correction).

BACS= Brief Assessment of Cognition in Schizophrenia, QLS=Quality of Life Scale.


2. Lehman AF : A quality of life interview for the chronically mental ill. *Eval Program Plann* 11 : 51-62, 1988
3. Meltzer HY : Outcome in schizophrenia : beyond symptom reduction. *J Clin Psychiatry* 60 (Suppl 3) : 3-7, 1999
4. Attikisson C, Cook J, Karno M : Caring for people with severe mental disorders : clinical services research. *Schizophr Bull* 18 : 561-626, 1992
5. Fitzgerald PB, Williams CL, Corteling N, Filia SL, Brewer K, Adams A, de Castella AR, Rolfe T, Davey P, Kulkarni J : Subject and observer-rated quality of life in schizophrenia. *Acta Psychiatr Scand* 103 : 387-392, 2001
6. Taniguchi T, Sumitani S, Aono M, Iga J, Kinouchi S, Aki H, Matsushita M, Taniguchi K, Tsuno M, Yamanishi K, Tomotake M, Kaneda Y, Ohmori T : Effect of antipsychotic replacement with quetiapine on the symptoms and quality of life of schizophrenic patients with extrapyramidal symptoms. *Hum Psychopharmacol* 21 : 439-445, 2006
7. Saxena S, Orley J : Quality of life assessment : the world health organization perspective. *Eur Psychiatry* 12 (Suppl 3) : 263-266, 1997
8. Voruganti L, Heslegrave R, Awad AG, Seeman MV : Quality of life measurement in schizophrenia : reconciling the quest for subjectivity with the question of reliability. *Psychol Med* 28 : 165-172, 1998
9. Heinrichs DW, Hanlon TE, Carpenter WT : The Quality of Life Scale : an instrument for rating the schizophrenic deficit symptoms. *Schizophr Bull* 10 : 388-398, 1984
10. Wilkinson G, Hesdon B, Wild D, Cookson R, Farina C, Sharma V, Fitzpatrick R, Jenkinson C : Self-report quality of life measure for people with schizophrenia : the SQLS. *Br J Psychiatry* 177 : 42-46, 2000
11. Kaneda Y, Imakura A, Fujii A, Ohmori T : Schizophrenia quality of life scale : validation of the Japanese version. *Psychiatry Res* 113 : 107-113, 2002
12. Dickerson FB, Ringel NB, Parente F : Subjective quality of life in out-patients with schizophrenia : clinical and utilization correlates. *Acta Psychiatr Scand* 98 : 124-127, 1998
13. Tomotake M, Kaneda Y, Iga J, Kinouchi S, Tayoshi S, Motoki I, Sumitani S, Yamauchi K, Taniguchi T, Ishimoto Y, Ueno S, Ohmori T : Subjective and objective measures of quality of life have different predictors in people with schizophrenia. *Psychol Rep* 99 : 477-487, 2006
14. Huppert JD, Weiss KA, Lim R, Pratt S, Smith TE : Quality of life in schizophrenia : contribution of anxiety and depression. *Schizophr Res* 51 : 171-180, 2001
15. Reine G, Lancon C, Di Tucci S, Sapin C, Auquier P : Depression and subjective quality of life in chronic phase schizophrenic patients. *Acta Psychiatr Scand* 108 : 297-303, 2003
16. Norman RMG, Malla AK, McLean T, Voruganti LPN, Cortese L, McIntosh E, Cheng S, Rickwood A : The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. *Acta Psychiatr Scand* 102 : 303-309, 2000
17. Bow-Thomas CC, Velligan DI, Miller AL, Olsen J : Predicting quality of life from symptomatology in schizophrenia at exacerbation and stabilization. *Psychiatry Res* 86 : 131-142, 1999
18. Browne S, Garavan J, Gervin M, Roe M, Larkin C, O'callaghan E : Quality of life in schizophrenia : insight and subjective response to neuroleptics. *J Nerv Ment Dis* 186 : 74-78, 1998
19. Browne S, Roe M, Lane A, Gervin M, Morris M, Kinsella A, Larkin C, Callaghan EO : Quality of life in schizophrenia : relationship to sociodemographic factors, symptomatology and tardive dyskinesia. *Acta Psychiatr Scand* 94 : 118-124, 1996
20. Meltzer HY, Burnett S, Bastani B, Ramirez LF : Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. *Hosp Community Psychiatry* 41 : 892-897, 1990
21. Parker G, O'Donnell M, Hadzi-Pavlovic D, Proberts M : Assessing outcome in community mental health patients : a comparative analysis of measures. *Int J Soc Psychiatry* 48 : 11-19, 2002
22. Aki H, Tomotake M, Kaneda Y, Iga J, Kinouchi S, Tayoshi S, Moriguchi K, Motoki I, Sumitani S, Yamauchi K, Taniguchi T, Ishimoto Y, Ueno S, Ohmori T : Subjective and objective quality of life, levels of life skills, and their clinical determinants in outpatients with schizophrenia. *Psychiatry Res* 158 : 19-25, 2008
23. Rosen A, Hadzi-Pavlovic D, Parker G : The life skills profile : a measure assessing function and disability in schizophrenia. *Schizophr Bull* 15 : 325-337, 1989

24. Targum SD, Keefe RSE : Cognition and schizophrenia : is there a role for cognitive assessments in diagnosis and treatment? *Psychiatry* 5 : 55-59, 2008
25. Heinrichs RW, Zakzanis KK : Neurocognitive deficits in schizophrenia : a quantitative review of the evidence. *Neuropsychology* 12 : 426-445, 1998
26. Gold JM : Cognitive deficits as treatment targets in schizophrenia. *Schizophr Res* 72 : 21-28, 2004
27. Kraus MS, Keefe RSE : Cognition as an outcome measure in schizophrenia. *Br J Psychiatry* 191 (Suppl 50) : 46-51, 2007
28. Savilla K, Kettler L, Galletly C : Relationships between cognitive deficits, symptoms and quality of life in schizophrenia. *Aust N Z J Psychiatry* 42 : 496-504, 2008
29. Addington J, Addington D : Neurocognitive and social functioning in schizophrenia : a 2.5 year follow-up study. *Schizophr Res* 44 : 47-56, 2000
30. Bozikas VP, Kosmidis MH, Kafantari A, Gamvrula K, Vasiliadou E, Petrikis P, Fokas K, Karavatos A : Community dysfunction in schizophrenia : rate-limiting factors. *Prog Neuropsychopharmacol Biol Psychiatry* 30 : 463-470, 2006
31. Ritsner MS : Predicting quality of life impairment in chronic schizophrenia from cognitive variables. *Qual Life Res* 16 : 929-937, 2007
32. Matsui M, Sumiyoshi T, Arai H, Higuchi Y, Kurachi M : Cognitive functioning related to quality of life in schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 32 : 280-287, 2008
33. Breier A, Schreiber JL, Dyer J, Pickar D : National Institute of Mental Health longitudinal study of chronic schizophrenia : prognosis and predictors of outcome. *Arch Gen Psychiatry* 48 : 239-246, 1991
34. Green MF : What are the functional consequences of neurocognitive deficits in schizophrenia? *Am J Psychiatry* 153 : 321-330, 1996
35. Ho BC, Nopoulos P, Flaum M, Arndt S, Andreasen NC : Two-year outcome in first-episode schizophrenia : predictive value of symptoms for quality of life. *Am J Psychiatry* 155 : 1196-1201, 1998
36. Wegener S, Redoblado-Hodge MA, Lucas S, Fitzgerald D, Harris A, Brennan J : Relative contributions of psychiatric symptoms and neuropsychological functioning to quality of life in first-episode psychosis. *Aust N Z J Psychiatry* 39 : 87-92, 2005
37. Yamauchi K, Aki H, Tomotake M, Iga J, Numata S, Motoki I, Izaki Y, Tayoshi S, Kinouchi S, Sumitani S, Tayoshi S, Takikawa Y, Kaneda Y, Taniguchi K, Ishimoto Y, Ueno S, Ohmori T : Predictors of subjective and objective quality of life in outpatients with schizophrenia. *Psychiatry Clin Neurosci* 62 : 404-411, 2008
38. Ueoka Y, Tomotake M, Tanaka T, Kaneda Y, Taniguchi K, Nakataki M, Numata S, Tayoshi S, Yamauchi K, Sumitani S, Ohmori T, Ueno SI, Ohmori T : Quality of life and cognitive dysfunction in people with schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 35 : 53-59, 2011
39. Keefe RSE, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L : The Brief Assessment of Cognition in Schizophrenia : reliability, sensitivity, and comparison with a standard neurocognitive battery. *Schizophr Res* 68 : 283-297, 2004
40. Kaneda Y, Sumiyoshi T, Keefe RSE, Ishimoto Y, Numata S, Ohmori T : Brief Assessment of Cognition in Schizophrenia : validation of the Japanese version. *Psychiatry Clin Neurosci* 6 : 602-609, 2007
41. Tomotake M, Ueoka Y, Tanaka T, Kaneda Y, Ohmori T : Effect of cognitive dysfunction on subjective quality of life in people with schizophrenia. *British Association of Behavioral and Cognitive Psychotherapies 38<sup>th</sup> Annual Conference, Manchester, 2010*



Contents lists available at ScienceDirect

# Progress in Neuro-Psychopharmacology & Biological Psychiatry

journal homepage: [www.elsevier.com/locate/pnp](http://www.elsevier.com/locate/pnp)

## Quality of life and cognitive dysfunction in people with schizophrenia

Yoshinori Ueoka <sup>a,\*</sup>, Masahito Tomotake <sup>b,1</sup>, Tsunehiko Tanaka <sup>a,2</sup>, Yasuhiro Kaneda <sup>c,3</sup>, Kyoko Taniguchi <sup>a,2</sup>, Masahito Nakataki <sup>a,2</sup>, Shusuke Numata <sup>a,2</sup>, Shinya Tayoshi <sup>a,2</sup>, Ken Yamauchi <sup>a,2</sup>, Satsuki Sumitani <sup>a,2</sup>, Takashi Ohmori <sup>a,2</sup>, Shu-ichi Ueno <sup>d,4</sup>, Tetsuro Ohmori <sup>a,2</sup>

<sup>a</sup> Department of Psychiatry, Institute of Health Bioscience, The University of Tokushima Graduate School, Japan

<sup>b</sup> Department of Mental Health, Institute of Health Bioscience, The University of Tokushima Graduate School, Japan

<sup>c</sup> Department of Psychiatry, Iwaki Clinic, Japan

<sup>d</sup> Department of Neuropsychiatry, Neuroscience, Ehime University Graduate School of Medicine, Japan

### ARTICLE INFO

#### Article history:

Received 5 December 2009

Received in revised form 3 August 2010

Accepted 21 August 2010

Available online 8 September 2010

#### Keywords:

Cognitive function

Quality of life

Schizophrenia

### ABSTRACT

The main purpose of the present study was to examine the relationship between quality of life (QOL) and cognitive dysfunction in schizophrenia. Subjects were 61 stabilized outpatients. Quality of life and cognitive function were assessed using the Quality of Life Scale (QLS) and the Brief Assessment of Cognition in Schizophrenia (BACS), respectively. Clinical symptoms were evaluated with the Positive and Negative Syndrome Scale (PANSS) and the Calgary Depression Scale for Schizophrenia (CDSS). The BACS composite score and the BACS Verbal memory score were positively correlated with the QLS total score and two subscales. The BACS Attention and speed of information processing score had positive correlation with the QLS total and all the subscales scores. The PANSS Positive and Negative syndrome scores also had significant correlations with the QLS total score and all of the subscales. In addition, the CDSS score was negatively correlated with the QLS total score and some of the subscales. Stepwise regression analysis showed that the BACS Attention and speed of information processing score was an independent predictor of the QLS total score but it was less associated with the QLS than the PANSS Negative syndrome score and the CDSS score. The results suggest that negative and depressive symptoms are important factors on patients' QOL and also support the view that cognitive performance provides a determinant of QOL in patients with schizophrenia.

© 2010 Elsevier Inc. All rights reserved.

**Abbreviations:** BACS, the Brief Assessment of Cognition in Schizophrenia; CDSS, the Calgary Depression Scale for Schizophrenia; DIEPSS, the Drug-Induced Extrapyramidal Symptoms Scale; PANSS, the Positive and Negative Syndrome Scale; QLS, the Quality of Life Scale; QOL, quality of life.

\* Corresponding author. 3-18-15, Kuramoto-cho, Tokushima-shi, Tokushima 770-8503, Japan. Tel.: +81 88 633 7130; fax: +81 88 633 7131.

E-mail addresses: [y-aiueo@ktd.biglobe.ne.jp](mailto:y-aiueo@ktd.biglobe.ne.jp) (Y. Ueoka), [tomotake@medsci.tokushima-u.ac.jp](mailto:tomotake@medsci.tokushima-u.ac.jp) (M. Tomotake), [maxterjp@yahoo.co.jp](mailto:maxterjp@yahoo.co.jp) (T. Tanaka), [kaneday-tsh@umin.ac.jp](mailto:kaneday-tsh@umin.ac.jp) (Y. Kaneda), [kyota0522@almond.ocn.ne.jp](mailto:kyota0522@almond.ocn.ne.jp) (K. Taniguchi), [nktk@clin.med.tokushima-u.ac.jp](mailto:nktk@clin.med.tokushima-u.ac.jp) (M. Nakataki), [shu-numata@umin.ac.jp](mailto:shu-numata@umin.ac.jp) (S. Numata), [stato-tyk@umin.ac.jp](mailto:stato-tyk@umin.ac.jp) (S. Tayoshi), [kandy7371@hotmail.com](mailto:kandy7371@hotmail.com) (K. Yamauchi), [satsuki@clin.med.tokushima-u.ac.jp](mailto:satsuki@clin.med.tokushima-u.ac.jp) (S. Sumitani), [taka-psy@clin.med.tokushima-u.ac.jp](mailto:taka-psy@clin.med.tokushima-u.ac.jp) (T. Ohmori), [ueno@m.ehime-u.ac.jp](mailto:ueno@m.ehime-u.ac.jp) (S. Ueno), [tohori@clin.med.tokushima-u.ac.jp](mailto:tohori@clin.med.tokushima-u.ac.jp) (T. Ohmori).

<sup>1</sup> 3-18-15, Kuramoto-cho, Tokushima-shi, Tokushima 770-8503, Japan. Tel.: +81 88 633 9083; fax: +81 88 633 9083.

<sup>2</sup> 3-18-15, Kuramoto-cho, Tokushima-shi, Tokushima 770-8503, Japan. Tel.: +81 88 633 7130; fax: +81 88 633 7131.

<sup>3</sup> 11-1, Kamimizuta, Gakubara-cho, Anan-shi, Tokushima 774-0014, Japan. Tel.: +81 884 23 5600; fax: +81 884 22 1720.

<sup>4</sup> Shitsukawa, Toon-shi, Ehime 791-0295, Japan. Tel.: +81 89 960 5315; fax: +81 89 960 5317.

0278-5846/\$ – see front matter © 2010 Elsevier Inc. All rights reserved.  
doi:10.1016/j.pnpbp.2010.08.018

### 1. Introduction

Quality of life (QOL) is thought to be one of the key outcome variables in the treatment of schizophrenia (Matsui et al., 2008), and the importance of evaluating it has been increasing in patient care and clinical research. Previous studies have revealed that several clinical factors such as negative and positive symptoms, depressive symptoms, and extrapyramidal adverse effect are associated with lowered QOL (Browne et al., 1996; Dickerson et al., 1998; Smith et al., 1999; Norman et al., 2000; Fitzgerald et al., 2001; Rocca et al., 2005; Strejilevich et al., 2005; Bozikas et al., 2006; Hofer et al., 2006; Tomotake et al., 2006; Aki et al., 2008; Yamauchi et al., 2008). Moreover, Yamauchi et al. (2008) reported that QOL correlated with dose of antipsychotics, and Xiang et al. (2007) and Browne et al. (1996) demonstrated that number of hospitalizations and duration of illness were associated with QOL.

Recently, cognitive dysfunction has been paid much more attention because they may lead to poor social functioning. Cognitive dysfunction is thought to be a core feature of schizophrenia (Kraus and Keefe, 2007), and it has been reported that cognitive functions of schizophrenia patients are of the order of one to two standard deviations below the mean of healthy controls in several cognitive dimensions, particularly memory, attention, verbal fluency, and executive function (Heinrichs